Research Progress of Targeting the CD47/SIRP-α Axis in Ovarian Cancer Treatment
WANG Xinyu# , XIE Zhitao# , ZHANG Menghui# , GAO Xiangzheng, ZHAN Jinbiao*
CD47, an innate immune checkpoint, which is highly expressed on ovarian cancer cells, can transmit the “Don’t eat me” signal when combined with SIRP-α on the surface of macrophages, thereby enabling tumors to escape from the immune system. Studies have suggested that high expression of CD47 on ovarian cancer cells is an independent risk factor for poor prognosis and platinum resistance. So far, both researches in vitro and in vivo and clinical trials about ovarian cancer treatment-related strategies of targeting the CD47/SIRP-α axis have shown significant results with broad application prospects. This article reviews the progress of targeting the CD47/ SIRP-α axis in ovarian cancer, providing new strategies for the clinical treatment of ovarian cancer.
CN
EN